Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/EPHB2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/EPHB2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/EPHB2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/EPHB2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/EPHB2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/EPHB2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0045936111 | Esophagus | ESCC | negative regulation of phosphate metabolic process | 273/8552 | 441/18723 | 3.18e-12 | 1.25e-10 | 273 |
GO:0051348111 | Esophagus | ESCC | negative regulation of transferase activity | 177/8552 | 268/18723 | 1.08e-11 | 4.00e-10 | 177 |
GO:0042326111 | Esophagus | ESCC | negative regulation of phosphorylation | 237/8552 | 385/18723 | 1.86e-10 | 5.33e-09 | 237 |
GO:0001933111 | Esophagus | ESCC | negative regulation of protein phosphorylation | 213/8552 | 342/18723 | 3.54e-10 | 9.76e-09 | 213 |
GO:003367319 | Esophagus | ESCC | negative regulation of kinase activity | 154/8552 | 237/18723 | 1.38e-09 | 3.27e-08 | 154 |
GO:000646920 | Esophagus | ESCC | negative regulation of protein kinase activity | 140/8552 | 212/18723 | 1.53e-09 | 3.56e-08 | 140 |
GO:190547519 | Esophagus | ESCC | regulation of protein localization to membrane | 117/8552 | 175/18723 | 1.14e-08 | 2.26e-07 | 117 |
GO:000726510 | Esophagus | ESCC | Ras protein signal transduction | 201/8552 | 337/18723 | 1.44e-07 | 2.30e-06 | 201 |
GO:190437519 | Esophagus | ESCC | regulation of protein localization to cell periphery | 85/8552 | 125/18723 | 3.63e-07 | 5.06e-06 | 85 |
GO:004206027 | Esophagus | ESCC | wound healing | 243/8552 | 422/18723 | 4.62e-07 | 6.25e-06 | 243 |
GO:1903076110 | Esophagus | ESCC | regulation of protein localization to plasma membrane | 72/8552 | 104/18723 | 9.74e-07 | 1.23e-05 | 72 |
GO:190547719 | Esophagus | ESCC | positive regulation of protein localization to membrane | 73/8552 | 106/18723 | 1.13e-06 | 1.40e-05 | 73 |
GO:003367420 | Esophagus | ESCC | positive regulation of kinase activity | 260/8552 | 467/18723 | 7.26e-06 | 7.22e-05 | 260 |
GO:001072010 | Esophagus | ESCC | positive regulation of cell development | 172/8552 | 298/18723 | 1.74e-05 | 1.55e-04 | 172 |
GO:005076710 | Esophagus | ESCC | regulation of neurogenesis | 203/8552 | 364/18723 | 6.10e-05 | 4.68e-04 | 203 |
GO:00507697 | Esophagus | ESCC | positive regulation of neurogenesis | 131/8552 | 225/18723 | 9.71e-05 | 6.90e-04 | 131 |
GO:190437719 | Esophagus | ESCC | positive regulation of protein localization to cell periphery | 47/8552 | 69/18723 | 1.37e-04 | 9.27e-04 | 47 |
GO:190307817 | Esophagus | ESCC | positive regulation of protein localization to plasma membrane | 43/8552 | 62/18723 | 1.38e-04 | 9.35e-04 | 43 |
GO:006156415 | Esophagus | ESCC | axon development | 251/8552 | 467/18723 | 2.41e-04 | 1.49e-03 | 251 |
GO:001097516 | Esophagus | ESCC | regulation of neuron projection development | 240/8552 | 445/18723 | 2.48e-04 | 1.53e-03 | 240 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EPHB2 | SNV | Missense_Mutation | | c.2517N>G | p.Ile839Met | p.I839M | P29323 | protein_coding | deleterious(0.01) | probably_damaging(0.943) | TCGA-A7-A13D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
EPHB2 | SNV | Missense_Mutation | | c.2105N>A | p.Met702Lys | p.M702K | P29323 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | | SD |
EPHB2 | SNV | Missense_Mutation | novel | c.1955N>C | p.Ile652Thr | p.I652T | P29323 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
EPHB2 | SNV | Missense_Mutation | | c.2665A>G | p.Ser889Gly | p.S889G | P29323 | protein_coding | deleterious(0.01) | benign(0.371) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
EPHB2 | SNV | Missense_Mutation | | c.1627C>T | p.Leu543Phe | p.L543F | P29323 | protein_coding | deleterious(0.03) | benign(0.02) | TCGA-B6-A0RH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
EPHB2 | SNV | Missense_Mutation | | c.1549N>A | p.Gly517Arg | p.G517R | P29323 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
EPHB2 | SNV | Missense_Mutation | novel | c.293G>T | p.Ser98Ile | p.S98I | P29323 | protein_coding | deleterious(0) | possibly_damaging(0.821) | TCGA-GM-A2DD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | CR |
EPHB2 | SNV | Missense_Mutation | novel | c.1913N>A | p.Gly638Asp | p.G638D | P29323 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-V7-A7HQ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | letrozole | CR |
EPHB2 | SNV | Missense_Mutation | novel | c.200C>T | p.Ser67Leu | p.S67L | P29323 | protein_coding | deleterious(0.03) | benign(0.013) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
EPHB2 | SNV | Missense_Mutation | novel | c.1136T>C | p.Val379Ala | p.V379A | P29323 | protein_coding | deleterious(0.03) | probably_damaging(0.967) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2048 | EPHB2 | KINASE, CLINICALLY ACTIONABLE, TYROSINE KINASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | | MK-8353 | MK-8353 | |
2048 | EPHB2 | KINASE, CLINICALLY ACTIONABLE, TYROSINE KINASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | | KO-947 | | |
2048 | EPHB2 | KINASE, CLINICALLY ACTIONABLE, TYROSINE KINASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | inhibitor | 249565821 | | |
2048 | EPHB2 | KINASE, CLINICALLY ACTIONABLE, TYROSINE KINASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL24828 | VANDETANIB | |
2048 | EPHB2 | KINASE, CLINICALLY ACTIONABLE, TYROSINE KINASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | | BVD-523 | ULIXERTINIB | |
2048 | EPHB2 | KINASE, CLINICALLY ACTIONABLE, TYROSINE KINASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | inhibitor | 384403668 | | |
2048 | EPHB2 | KINASE, CLINICALLY ACTIONABLE, TYROSINE KINASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME | inhibitor | 381118815 | | |